PPARA and metabolic syndrome: While fenofibrate did not ameliorate liver histology in biopsy-proven NAFLD, a selective PPARα agonist, also known as Pemafibrate, did improve liver function in patients with dyslipidemia [130], which was previously established in diet-induced murine models of NAFLD [131].